Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 5/20 | 0.35 |
| ▸ | LMNA | P02545 | 4/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6634306 | 0.75 | PDE5A (0.56) | PDE5A | |
| SCHEMBL1887267 | 0.75 | PDE5A (0.56) | PDE5A | |
| SCHEMBL1891582 | 0.71 | PDE5A (0.59) | PDE5A | |
| SCHEMBL2509857 | 0.65 | PDE5A (0.60) | PDE5A | |
| SCHEMBL2502972 | 0.65 | PDE5A (0.60) | PDE5A | |
| SCHEMBL6407129 | 0.65 | PDE5A (0.58) | KDM4EHSD17B10ALOX15PDE5A | |
| SCHEMBL6407096 | 0.65 | PDE5A (0.58) | KDM4EHSD17B10ALOX15PDE5A | |
| Hydrochloric Acid SCHEMBL6407788 | 0.64 | PDE5A (0.59) | PDE5A | |
| Hydrochloric Acid SCHEMBL5537994 | 0.64 | PDE5A (0.59) | PDE5A | |
| SCHEMBL14629758 | 0.62 | KDM4E (0.35) | KDM4EALDH1A1SMN1; SMN2HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050113402-A1 | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | SUI ZHIHUA (US) | 2005-05-26 | — | — | US | disclosed |
| US-6818646-B2 | 1,2,3,4-TETRAHYDRO-2-(5-(2-PYRIDINYL)-PYRIMIDIN-2-YL)-3-(2,3 -DIHYDROBENZOFURANYL)-9H-PYRROLO-(3,4-B)QUINOLIN-9-ONE; MALE ERECTILE DYSFUNCTION; SEXUAL DISORDERS | SUI ZHIHUA (US) | 2004-11-16 | — | — | US | disclosed |
| EP-1296981-B1 | SUBSTITUTED PYRROLOPYRIDINONE DERIVATIVES USEFUL AS PHOSPHODIESTERASE INHIBITORS | ORTHO MCNEIL PHARM INC (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20040044021-A1 | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | SUI ZHIHUA (US) | 2004-03-04 | — | — | US | disclosed |
| US-6635638-B2 | Treatment of sexual dysfunction, cardiovascular system disorders | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-10-21 | — | — | US | disclosed |
| EP-1296981-A2 | SUBSTITUTED PYRROLOPYRIDINONE DERIVATIVES USEFUL AS PHOSPHODIESTERASE INHIBITORS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-04-02 | — | — | EP | disclosed |
| US-20020010183-A1 | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-01-24 | — | — | US | disclosed |
| WO-2001087882-A2 | SUBSTITUTED PYRROLOPYRIDINONE DERIVATIVES USEFUL AS PHOSPHODIESTERASE INHIBITORS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113402-A1 | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | PDE5A, PDE3A, PDE3B | KDM4E 1469/4885ALDH1A1 618/4885SMN1; SMN2 1990/4885 |
| US-20040044021-A1 | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | PDE5A, PDE3A, PDE3B | KDM4E 1486/4885ALDH1A1 498/4885SMN1; SMN2 1867/4885 |
| US-20020010183-A1 | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | PDE5A, PDE3A, PDE3B | KDM4E 1486/4885ALDH1A1 498/4885SMN1; SMN2 1867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.